I do wonder how much attention is paid by other pharma's when NEU announce another syndrome being added to the pipeline. I'm sure they have internal teams looking at these things and searching for opportunties. Someone mentioned it before or perhaps i read it in a report but if Trofinetide passes P3 it goes along way to de-risk NNZ-2591. With this pipeline one would think someone woudl be considering making a move on us.
Ann: Neuren adds Prader-Willi syndrome to NNZ-2591 pipeline, page-35
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.96 |
Change
0.000(0.00%) |
Mkt cap ! $1.609B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.70 | $2.468M | 191.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 151 | $12.95 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.96 | 114 | 4 |
View Market Depth
| Last trade - 13.37pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |